4-amino-N-(3-(dimethylamino)propyl)benzamide | 53461-08-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-amino-N-(3-(dimethylamino)propyl)benzamide
• 英文别名: 4-amino-benzoic acid-(3-dimethylamino-propylamide)；4-Amino-benzoesaeure-(3-dimethylamino-propylamid)；N,N-Dimethyl-N'-(4-amino-benzoyl)-propandiyldiamin；4-Amino-N-(3-dimethylamino-propyl)-benzamid；4-amino-N-[3-(dimethylamino)propyl]benzamide
• CAS: 53461-08-8
• 化学式: C₁₂H₁₉N₃O
• mdl: MFCD07658151
• 分子量: 221.302
• InChiKey: FEMQIZGAEIBWQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  58.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-amino-N-(3-(dimethylamino)propyl)benzamide 在 palladium on activated charcoal 吡啶 、 盐酸 、 4-二甲氨基吡啶 、 氢气 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 N-[5-(5-amino-2-methoxybenzamido)benzoyl]-N',N'-dimethylpropyl-1,3-diamine dihydrochloride
  参考文献：
  名称：

  Aromatic analogues of DNA minor groove binders—synthesis and biological evaluation

  摘要：

  Nine carbocyclic analogues of mono- and bis-lexitropsins and two analogues of pentamidine with unsubstituted N-terminal amine group were synthesized. We have investigated the cytotoxic activity of new aromatic analogues of DNA binding ligands in MCF-7 breast cancer cells and assessed their ability to act as inhibitors of topoisomerase I and II. These studies indicate that aromatic analogues of bis-netropsin contain two identical units tethered by alkyloxyl chains are a potent catalytic inhibitor of both topoisomerases and exhibit moderate cytotoxicity in MCF-7 breast cancer cells. (C) 2003 Elsevier SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2003.11.005
• 作为产物：
  描述：

  N-BOC-4-氨基苯甲酸 在 盐酸 、 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 4-amino-N-(3-(dimethylamino)propyl)benzamide
  参考文献：
  名称：

  带有扩展侧链的铂（II）苯基菲并咪唑从ac-Kit G-Quadruplex母题中显示出缓慢的解离

  摘要：

  甲系列三个铂（II）phenanthroimidazoles各自含有可质子化的侧链通过从铜苯基部分所附（I）催化的叠氮化物-炔烃环加成加成（CuAAC）测试它们的能力结合人端粒评价，c-Myc的，和c-Kit衍生的G-四链体。侧链已经过优化，可实现与G四联体基序的多价结合模式，这有可能导致选择性靶向。分子建模，高通量荧光嵌入剂置换（HT-FID）分析和表面等离振子共振（SPR）研究表明，与没有侧链和其他已报道的G四联体键合的铂菲并咪唑相比，复合物2的离解速率显着降低。复杂的2在HeLa和A172癌细胞系中几乎没有细胞毒性，这与不遵循端粒靶向途径这一事实是一致的。初步的mRNA分析显示2与ckit启动子区域特异性相互作用。总的来说，这项研究验证了2是与c‐Kit相关的癌症途径的有用分子探针。

  DOI：

  10.1002/chem.201301590

文献信息

• HALO-SUBSTITUTED PYRIMIDODIAZEPINES
  申请人：Cai Jianping

  公开号：US20090318408A1

  公开（公告）日：2009-12-24

  The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.

  本发明提供了公式I的PLK1抑制剂化合物： 用于治疗或控制细胞增殖性疾病，特别是肿瘤性疾病。这些化合物和含有这些化合物的配方可能在治疗或控制实体肿瘤方面有用，例如乳腺癌、结肠癌、肺癌和前列腺癌等固体肿瘤，以及非霍奇金淋巴瘤等其他肿瘤性疾病。还提供了在合成公式I化合物中有用的中间体化合物。
• Anti-Cytokine Heterocyclic Compounds
  申请人：Goldberg Daniel

  公开号：US20060276496A1

  公开（公告）日：2006-12-07

  Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.

  杂环化合物及其类似物以及它们作为丝裂原活化蛋白激酶-2（MAPKAP-k2）抑制剂的用途，以及用于预防或治疗可以通过调节受试者中MAPKAP-K2活性来治疗或预防的疾病或紊乱的方法，以及包括这些MAPKAP-K2抑制剂的药物组合物和试剂盒。
• [EN] AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON<br/>[FR] COMPOSÉS D'AMINO-PYRIMIDINE EN TANT QU'INHIBITEURS DE TBKL ET OU D'IKK EPSILON
  申请人：MYREXIS INC

  公开号：WO2011046970A1

  公开（公告）日：2011-04-21

  The invention relates to certain amino-pyrimidine compounds which inhibit TBK1 and/or IKK epsilon and which may therefore find application in treating inflammation, cancer, septic shock and/or Primary open Angle Glaucoma (POAG).

  这项发明涉及抑制TBK1和/或IKK epsilon的某些氨基嘧啶化合物，因此可能在治疗炎症、癌症、感染性休克和/或原发性开角青光眼（POAG）中找到应用。
• Substituted indolinones
  申请人：——

  公开号：US20030092756A1

  公开（公告）日：2003-05-15

  The present invention relates to indolinones substituted in the 6-position of general formula 1 wherein R 1 to R 5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and cyclin/CDK complexes and on the proliferation of endothelial cells and various, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一种通式1中6位取代的吲哚酮，其中R1至R5和X的定义如权利要求1中定义的，其异构体和盐，特别是具有有价值的药理特性的生理上可接受的盐，特别是对各种受体酪氨酸激酶和细胞周期蛋白/CDK复合物以及内皮细胞增殖具有抑制作用的物质，含有这些化合物的药物组合物，其用途和制备这些化合物的方法。
• Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
  申请人：Heckel Armin

  公开号：US20060194813A1

  公开（公告）日：2006-08-31

  The present invention relates to indolinone derivatives substituted in the 6 position of general formula wherein R 1 to R 6 and X are defined as in claim 1 , the tautomers, enantiomers, diastereomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof, which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一种在通式中6位取代的吲哚酮衍生物，其中R1至R6和X如权利要求1所定义，其互变异构体、对映异构体、顺反异构体、混合物及其盐，特别是其生理上可接受的盐，具有有价值的药理特性，特别是对各种受体酪氨酸激酶和内皮细胞以及各种肿瘤细胞的增殖具有抑制作用，包含这些化合物的制药组合物，它们的用途和制备过程。